For regulatory and clinical development teams working on plasma-derived immunoglobulin products, understanding what non-clinical data package EMA considers adequate is critical to planning a compliant Module 4 submission and drafting an accurate SmPC section 5.3. Because human polyvalent immunoglobulins occupy an unusual position—simultaneously a therapeutic product and a normal constituent of the human body—the agency applies a distinct scientific rationale that departs from the standard non-clinical toxicology expectations for small molecules or recombinant biologics.
This analysis examines the EMA scientific guidelines governing intravenous, subcutaneous, and intramuscular human normal immunoglobulin preparations alongside the published EPARs for authorised polyvalent immunoglobulin products, in order to map the accepted non-clinical data framework across the key toxicology domains: single-dose, repeated-dose, local tolerance, reproductive and developmental toxicity, genotoxicity, and carcinogenicity.
Want Rhizome's help on your own question? Try it for free.
Non-clinical toxicity data EMA accepts for human polyvalent immunoglobulins
The short answer
For polyvalent human immunoglobulins, EMA does not expect the conventional toxicology battery. The governing scientific principle, stated across assessment reports, is that human immunoglobulins are heterologous (foreign) proteins in animals, so repeat administration induces anti-human-immunoglobulin antibodies that interfere with exposure and confound interpretation. This makes repeated-dose toxicity, genotoxicity, reproductive/developmental toxicity and carcinogenicity studies impracticable or of limited value 313335. What EMA has actually accepted is a reduced package built around single-dose (acute) toxicity, local tolerance, safety pharmacology and pharmacodynamic/pharmacokinetic characterisation, supported by the argument that immunoglobulin G is a normal constituent of the human body 3180.
The accepted SmPC section 5.3 position
The core SmPC guideline for IVIg leaves section 5.3 "Preclinical safety data" as a product-specific field 51, but the harmonised wording that EMA has accepted in practice appears in authorised labels. The Kiovig product information states that immunoglobulins are a normal constituent of the human body, that repeated-dose toxicity, genotoxicity and reproductive toxicity studies in animals are impracticable due to induction of and interference by developing antibodies to heterologous proteins, and that because clinical experience provides no evidence of carcinogenic potential, no experimental carcinogenicity studies in heterologous species were performed 31. This is the template statement a reviewer will recognise across the class.
What EMA has accepted, by study type
Single-dose (acute) toxicity. This is the one general-toxicity study EMA has typically accepted and, in several cases, expected. For Kiovig, acute/single-dose studies in mice and rats showed no treatment-related clinical or histopathological findings, with a NOAEL of 5,000 mg/kg in mice and 2,000 mg/kg in rats 80. Flebogamma DIF relied on acute intravenous toxicity studies in mice and rats as the core safety battery 8690. Notably, EMA also accepts no single-dose study at all where a well-characterised reference product supports the file: for Deqsiga (TAK-880) no single-dose toxicity study was performed, and Kiovig data were accepted as applicable because the products share characteristics apart from IgA/IgG4 differences 33.
Repeated-dose toxicity. Generally waived. EMA accepted the absence of repeat-dose studies for Kiovig, Privigen, Deqsiga and Hizentra on the grounds that antigenicity/antibody formation in animals makes such studies uninterpretable for human immunoglobulins 31323380. The exception in this dataset is HyQvia, where the recombinant human hyaluronidase (rHuPH20) component, not the immunoglobulin, drove a genuine repeat-dose program: rhesus monkey single/repeat weekly SC studies gave a NOAEL of 38,800 U/injection (12,000 U/kg) with no neutralising antibodies detected, and a 6-week intravesical cynomolgus study showed no treatment-related findings 76.
Local tolerance. Consistently expected and accepted, since it addresses the actual route of administration. Privigen submitted a rabbit local-tolerance program supporting subcutaneous, intravenous and intra-arterial administration, with only slight, early paravenous irritation 32. Kiovig included rabbit local-tolerance work 34, and Deqsiga was allowed to rely on Kiovig local-tolerance data because the formulations are identical 33. HyQvia added a repeat-dose local-tolerance study in rats 39, and Zutectra's subcutaneous local tolerance was investigated and found well tolerated 95.
Reproductive/developmental toxicity. Waived for the immunoglobulin itself. EMA accepted that such studies are not required for human plasma-derived immunoglobulin products because human immunoglobulin has no relevant interaction in animal models 2932. Where a novel excipient or component is present, EMA did require data on that component: Privigen provided a teratogenicity (segment II) study of the excipient L-proline in rats, which showed no maternal, embryo-toxic or teratogenic effects at 1,449 mg/kg/day 32; HyQvia provided mouse embryo-foetal and peri/post-natal studies of rHuPH20 (embryo-foetal NOAEL 3.0 mg/kg; maternal/offspring NOAEL 9 mg/kg/day), with anti-rHuPH20 antibodies detected in dams but judged not causally related to the foetal findings 77.
Genotoxicity. Not required for the immunoglobulin. Where genotoxicity data appear, they concern excipients or a reference lot: an Ames test on a Kiovig lot was negative 3033, and Privigen's L-proline was assessed by Ames and mouse bone-marrow micronucleus testing and found non-mutagenic 32.
Carcinogenicity. Not performed. EMA accepted that carcinogenicity studies are inappropriate for human IgG and that clinical experience provides no signal of carcinogenic potential 3132. For specific immunoglobulins with limited-duration use, the short treatment period (not expected to exceed six months) was also cited as justification 29.
Product-by-product snapshot
| Product (route) | Single-dose tox | Repeat-dose tox | Local tolerance | Reproductive/dev tox | Genotox / Carcinogenicity | Citation |
|---|---|---|---|---|---|---|
| Kiovig (IVIg) | Mice/rats, no findings; NOAEL 5,000 mg/kg (mouse), 2,000 mg/kg (rat) | Waived (antigenicity) | Rabbit studies included | Impracticable | Impracticable / none performed | 313480 |
| Privigen (IVIg) | Not detailed in rows | Waived (impracticable) | Rabbit s.c./i.v./i.a. supported; slight early p.v. irritation | Not conducted; L-proline teratogenicity negative | L-proline Ames + micronucleus negative / not appropriate for IgG | 32 |
| Hizentra (SCIg) | Not detailed | Limited value; not required | Rabbit local tolerance | Limited value | Limited value | 3582 |
| HyQvia (IG + rHuPH20) | rHuPH20 IV rat: slight renal tubule dilation | rHuPH20: monkey NOAEL 38,800 U/inj; no neutralising Ab | Repeat-dose rat local tolerance | rHuPH20 mouse studies; NOAEL 3.0 mg/kg (embryo-foetal) | Not reported in rows | 397677 |
| Deqsiga / TAK-880 (IG) | None; Kiovig data accepted | Not performed; accepted | None; Kiovig data accepted (same formulation) | Not performed; accepted | Kiovig Ames negative / not performed | 3033 |
| Flebogamma DIF (IVIg) | Acute IV mice/rats | Not indicated | — | — | No special concern | 8690 |
Reviewer takeaways
The consistent EMA position is that the polyvalent immunoglobulin active substance is exempt from the standard chronic toxicology battery on a well-established scientific rationale, and that an applicant's non-clinical file is expected to cover single-dose toxicity and local tolerance, plus safety pharmacology and PD/PK/antigenicity characterisation 31323580. Two practical consequences follow. First, cross-referencing an authorised reference product (as Deqsiga did with Kiovig) is an accepted way to satisfy single-dose toxicity and local tolerance where formulations match 33. Second, any non-immunoglobulin component (a novel excipient such as L-proline, or an enzyme such as rHuPH20) is assessed on its own and can trigger a full set of genotoxicity and reproductive-toxicity studies that the immunoglobulin itself would not 327677. A natural follow-up for a specific dossier would be to pull the exact section 5.3 label wording and the Module 4 study list for the individual product of interest.